Full Program Just Released!
Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, July 10 & Save up to $700

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Analyzing the ADC Boom & Contextualizing an Increasingly Busy Clinical Bioconjugate Landscape

Analyzing the ADC Boom & Contextualizing an Increasingly Busy Clinical Bioconjugate Landscape

By | 8 June 2026

Exploring trends and updates from preclinical and clinical ADC development • Reviewing key highlights for ADC innovation and development in 2025 and 2026
Examining emerging ADC approaches including dual payloads, bispecific ADCs and DACs
Visualizing the history of ADC development, giving perspective on how far the ADC space has come and where it is heading